Oral viscous budesonide vs swallowed fluticasone
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review
- no estimate extracted1 study · 84 participantsLow
Findings
What do systematic reviews say?
4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only
No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Oral viscous budesonide vs swallowed fluticasone
Histological improvement (dichotomous) · active EoE patients
Oral viscous budesonide showed no clear difference in histological improvement at study endpoint (dichotomous) compared with swallowed fluticasone (low certainty).
1 finding from 1 review
- RR 1.13 [0.84, 1.51]1 study · 129 participantsLow
Oral viscous budesonide vs swallowed fluticasone
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
- no estimate extracted1 study · 111 participantsLow
Oral viscous budesonide vs swallowed fluticasone
Endoscopic improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral viscous budesonide vs swallowed fluticasone
Endoscopic improvement (continuous) · active EoE patients
1 finding from 1 review
- no estimate extracted1 study · 111 participantsLow
Oral viscous budesonide vs swallowed fluticasone
Withdrawals due to adverse events · active EoE patients
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
1 finding from 1 review
- RR 0.98 [0.42, 2.32]1 study · 129 participantsLow
Varenicline vs e‐cigarettes
Smoking abstinence at longest · people who continued to smoke tobacco following acute coronary syndrome
It is very uncertain whether varenicline changes smoking abstinence at longest compared with e‐cigarettes (very low certainty).
1 finding from 1 review
- RR 3.25 [1.21, 8.71]1 study · 54 participantsVery low
Varenicline vs e‐cigarettes
SAEs · people who continued to smoke tobacco following acute coronary syndrome
1 finding from 1 review
- no estimate extracted1 study · 54 participantsGRADE not reported
Varenicline vs e‐cigarettes
Neuropsychiatric SAEs · people who continued to smoke tobacco following acute coronary syndrome
1 finding from 1 review
- no estimate extracted1 study · 54 participantsGRADE not reported
Varenicline vs e‐cigarettes
Cardiac SAEs · people who continued to smoke tobacco following acute coronary syndrome
1 finding from 1 review
- no estimate extracted1 study · 54 participantsGRADE not reported
High vs low dose pegylated interferon alpha‐2a or alpha‐2b
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
High vs low dose pegylated interferon alpha‐2a or alpha‐2b
PEG interferon alpha‐2a · patients on HD with HCV infection
High showed no clear difference in PEG interferon alpha‐2a compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
4 findings from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 5.66 [0.69, 46.31]1 study · 81 participantsLow
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 1.12 [0.4, 2.21]1 study · 43 participantsLow
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 1.19 [0.79, 1.78]1 study · 81 participantsLow
Show 1 more finding
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 1.13 [0.64, 2]1 study · 81 participantsLow
High vs low dose pegylated interferon alpha‐2a or alpha‐2b
PEG interferon (alpha‐2b) · patients on HD with HCV infection
High showed no clear difference in PEG interferon alpha‐2b compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
2 findings from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 2.4 [0.11, 51.32]1 study · 16 participantsLow
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 5.6 [0.34, 93.35]1 study · 16 participantsLow
High vs low dose pegylated interferon alpha‐2a or alpha‐2b
PEG interferon (combined) · patients on HD with HCV infection
High showed no clear difference in PEG interferon (combined) compared with low dose pegylated interferon alpha‐2a or alpha‐2b (moderate certainty).
3 findings from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 4.3 [0.76, 24.33]2 studies · 97 participantsModerate
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 1.12 [0.4, 2.21]1 study · 43 participantsLow
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 1.05 [0.61, 1.83]2 studies · 97 participantsModerate
High vs low dose pegylated interferon alpha‐2a or alpha‐2b
End‐of‐treatment response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
High vs low dose pegylated interferon alpha‐2a or alpha‐2b
Treatment discontinuation · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
High vs low dose pegylated interferon alpha‐2a or alpha‐2b
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
High vs low dose pegylated interferon alpha‐2a or alpha‐2b
Serious adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)
Relapse · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found